These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1193 related items for PubMed ID: 12748668

  • 1. A potential graft-versus-leukemia effect after allogeneic hematopoietic stem cell transplantation for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: results from the French Bone Marrow Transplantation Society.
    Espérou H, Boiron JM, Cayuela JM, Blanchet O, Kuentz M, Jouet JP, Milpied N, Cahn JY, Faucher C, Bourhis JH, Michallet M, Tanguy ML, Vernant JP, Gabert J, Bordigoni P, Ifrah N, Baruchel A, Dombret H, French Bone Marrow Transplantation.
    Bone Marrow Transplant; 2003 May; 31(10):909-18. PubMed ID: 12748668
    [Abstract] [Full Text] [Related]

  • 2. Eradication of residual bcr-abl-positive clones by inducing graft-versus-host disease after allogeneic stem cell transplantation in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Matsue K, Tabayashi T, Yamada K, Takeuchi M.
    Bone Marrow Transplant; 2002 Jan; 29(1):63-6. PubMed ID: 11840146
    [Abstract] [Full Text] [Related]

  • 3. Donor Lymphocyte Infusions for Chronic Myeloid Leukemia Relapsing after Allogeneic Stem Cell Transplantation: May We Predict Graft-versus-Leukemia Without Graft-versus-Host Disease?
    Radujkovic A, Guglielmi C, Bergantini S, Iacobelli S, van Biezen A, Milojkovic D, Gratwohl A, Schattenberg AV, Verdonck LF, Niederwieser DW, de Witte T, Kröger N, Olavarria E, Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation.
    Biol Blood Marrow Transplant; 2015 Jul; 21(7):1230-6. PubMed ID: 25797175
    [Abstract] [Full Text] [Related]

  • 4. Distinct patterns of minimal residual disease associated with graft-versus-host disease after allogeneic bone marrow transplantation for chronic myelogenous leukemia.
    Pichert G, Roy DC, Gonin R, Alyea EP, Bélanger R, Gyger M, Perreault C, Bonny Y, Lerra I, Murray C.
    J Clin Oncol; 1995 Jul; 13(7):1704-13. PubMed ID: 7602361
    [Abstract] [Full Text] [Related]

  • 5. Favorable outcome of unrelated cord blood transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Onishi Y, Sasaki O, Ichikawa S, Inokura K, Katsuoka Y, Ohtsuka Ohba R, Okitsu Y, Kohata K, Ohguchi H, Fukuhara N, Yokoyama H, Yamada MF, Yamamoto J, Ishizawa K, Kameoka J, Harigae H.
    Biol Blood Marrow Transplant; 2011 Jul; 17(7):1093-7. PubMed ID: 21277378
    [Abstract] [Full Text] [Related]

  • 6. Role of pretransplant interferon-alpha(IFN) treatment in the outcome of stem cell transplantation (SCT) from related donors in chronic myelogenous leukemia (CML): results from three Turkish transplant centers.
    Beksac M, Celebi H, Sargín D, Yalcin A, Topcuoglu P, Kalayoglu-Besisik S, Beyan C, Arslan O, Ozcan M, Gurman G, Ilhan O, Akan H.
    Bone Marrow Transplant; 2003 May; 31(10):897-904. PubMed ID: 12748666
    [Abstract] [Full Text] [Related]

  • 7. [Effects and prognostic factors of HLA-matched sibling donor allogeneic hematopoietic stem cell transplantation for chronic myelogenous leukemia].
    Tong XZ, Li J, Tan EX, Zhang GC, Wu XY, Peng AH, Zheng D, Zou WY, Hong WD, Luo SK.
    Zhonghua Zhong Liu Za Zhi; 2006 Jul; 28(7):545-8. PubMed ID: 17147125
    [Abstract] [Full Text] [Related]

  • 8. Individualized intervention guided by BCR-ABL transcript levels after HLA-identical sibling donor transplantation improves HSCT outcomes for patients with chronic myeloid leukemia.
    Huang XJ, Xu LP, Liu KY, Liu DH, Chen H, Liu YR, Chen YH, Han W, Wang Y.
    Biol Blood Marrow Transplant; 2011 May; 17(5):649-56. PubMed ID: 20691800
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Outcome of allogeneic peripheral blood stem cell transplantation by donor graft CD3+/Tregs ratio: a single-center experience.
    Delia M, Pastore D, Mestice A, Carluccio P, Perrone T, Gaudio F, Ricco A, Sgherza N, Albano F, Specchia G.
    Biol Blood Marrow Transplant; 2013 Mar; 19(3):495-9. PubMed ID: 23200706
    [Abstract] [Full Text] [Related]

  • 12. Allogeneic cell-mediated immunotherapy using donor lymphocytes for prevention of relapse in patients treated with allogeneic bone marrow transplantation for hematological malignancies.
    Naparstek E, Nagler A, Or R, Kapelushnik J, Slavin S.
    Clin Transpl; 1996 Mar; ():281-90. PubMed ID: 9286578
    [Abstract] [Full Text] [Related]

  • 13. [The significance of serial monitoring of bcr-abl transcripts levels after allogeneic hematopoietic stem cell transplantation in screening chronic myeloid leukemia patients with low relapse].
    Xu LP, Liu KY, Huang XJ, Liu DH, Han W, Chen YH, Wang Y, Liu YR, Qin YZ.
    Zhonghua Xue Ye Xue Za Zhi; 2008 Aug; 29(8):522-5. PubMed ID: 19112914
    [Abstract] [Full Text] [Related]

  • 14. Imatinib mesylate (STI571) in preparation for allogeneic hematopoietic stem cell transplantation and donor lymphocyte infusions in patients with Philadelphia-positive acute leukemias.
    Shimoni A, Kröger N, Zander AR, Rowe JM, Hardan I, Avigdor A, Yeshurun M, Ben-Bassat I, Nagler A.
    Leukemia; 2003 Feb; 17(2):290-7. PubMed ID: 12592325
    [Abstract] [Full Text] [Related]

  • 15. The extent of minimal residual disease reduction after the first 4-week imatinib therapy determines outcome of allogeneic stem cell transplantation in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Lee S, Kim YJ, Chung NG, Lim J, Lee DG, Kim HJ, Min CK, Lee JW, Min WS, Kim CC.
    Cancer; 2009 Feb 01; 115(3):561-70. PubMed ID: 19117346
    [Abstract] [Full Text] [Related]

  • 16. [Hematopoietic stem cell transplantation for patients with chronic myelogenous leukemia].
    Liu QF, Sun J, Zhang Y, Liu XL, Xu D, Xu B, Feng R, Meng FY, Zhou SY.
    Ai Zheng; 2004 Apr 01; 23(4):426-9. PubMed ID: 15087032
    [Abstract] [Full Text] [Related]

  • 17. Donor leukocyte infusion for Japanese patients with relapsed leukemia after allogeneic bone marrow transplantation: lower incidence of acute graft-versus-host disease and improved outcome.
    Shiobara S, Nakao S, Ueda M, Yamazaki H, Takahashi S, Asano S, Yabe H, Kato S, Imoto S, Maruta A, Yoshida T, Gondo H, Morishima Y, Kodera Y.
    Bone Marrow Transplant; 2000 Oct 01; 26(7):769-74. PubMed ID: 11042659
    [Abstract] [Full Text] [Related]

  • 18. Donor lymphocyte infusions for relapse of chronic myeloid leukemia after allogeneic stem cell transplantation: prognostic significance of the dose of CD3(+) and CD4(+) lymphocytes.
    Vela-Ojeda J, García-Ruiz Esparza MA, Reyes-Maldonado E, Jiménez-Zamudio L, Moreno-Lafont M, García-Latorre E, Ramírez-Sanjuan E, Montiel-Cervantes L, Tripp-Villanueva F, García-León LD, Ayala-Sánchez M, Rosas-Cabral A, Aviña-Zubieta JA, Galindo-Rodríguez G, Vadillo-Buenfil M, Salazar-Exaire D.
    Ann Hematol; 2004 May 01; 83(5):295-301. PubMed ID: 15060749
    [Abstract] [Full Text] [Related]

  • 19. Molecular basis for therapeutic decisions in chronic myeloid leukemia patients after allogeneic bone marrow transplantation.
    Román J, Alvarez MA, Torres A.
    Haematologica; 2000 Oct 01; 85(10):1072-82. PubMed ID: 11025600
    [Abstract] [Full Text] [Related]

  • 20. A comparison of chimerism and minimal residual disease between four different allogeneic transplantation methods in patients with chronic myelogenous leukemia in first chronic phase.
    Elmaagacli AH, Runkel K, Steckel N, Opalka B, Trenschel R, Seeber S, Schaefer UW, Beelen DW.
    Bone Marrow Transplant; 2001 Apr 01; 27(8):809-15. PubMed ID: 11477437
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 60.